CellPress

Trends in Immunology

Special issue: Systems immunology

Review

Genotype–phenotype landscapes for immune–pathogen coevolution

Alief Moulana,[1,6] Thomas Dupic,[1,6] Angela M. Phillips,[2] and Michael M. Desai[1,3,4,5,*]

Our immune systems constantly coevolve with the pathogens that challenge them, as pathogens adapt to evade our defense responses, with our immune repertoires shifting in turn. These coevolutionary dynamics take place across a vast and high-dimensional landscape of potential pathogen and immune receptor sequence variants. Mapping the relationship between these genotypes and the phenotypes that determine immune–pathogen interactions is crucial for understanding, predicting, and controlling disease. Here, we review recent developments applying high-throughput methods to create large libraries of immune receptor and pathogen protein sequence variants and measure relevant phenotypes. We describe several approaches that probe different regions of the high-dimensional sequence space and comment on how combinations of these methods may offer novel insight into immune–pathogen coevolution.

Highlights

The set of all possible pathogen and immune receptor sequences, along with the phenotypes that define their fitness and interactions, define a large and high-dimensional landscape across which immune–pathogen coevolution takes place.

Recent high-throughput phenotyping assays exploit next-generation sequencing to measure relevant phenotypes of large libraries of pathogen or immune receptor sequences, dramatically increasing our ability to characterize the genotype–phenotype maps underlying immune–pathogen coevolution.

Three broad classes of approaches have been used to explore these coevolutionary landscapes. First, random or saturating mutagenesis methods analyze all (or many) variants in the direct mutational vicinity of a small set of focal sequences. Second, combinatorial methods make it possible to analyze all (or many) possible combinations of some specific set of mutations. Finally, directed evolution methods explore how focal sequences adapt across successive rounds of mutagenesis and selection.

Significance

Understanding immune–pathogen coevolution is essential for predicting and ultimately controlling disease. This coevolution takes place over a complex landscape defined by the relevant pathogen and immune receptor sequences, along with the phenotypes that determine how they interact. Thus, it is important to survey the recent high-throughput empirical methods that have transformed our ability to characterize the properties of large and high-dimensional genotype–phenotype maps and their implications for our understanding of immune–pathogen coevolutionary dynamics.

Immune–pathogen coevolution

Our adaptive immune systems are engaged in a continuous coevolutionary struggle with the pathogens that attack us [1,2]. This immune–pathogen coevolution takes place across a range of spatial and temporal scales: evolution in individual infections is driven by interactions between pathogens and an individual host immune system, often over the course of days or weeks, while global pathogen evolution is driven by the collective immune responses of whole, often geographically dispersed populations across years or decades [3–6]. This pathogen evolution, in turn, drives shifts in both individual and population-wide host immune repertoires [7–10]. The dynamics of this coevolutionary process within individuals and across the population is key to understanding, predicting, and ultimately controlling disease.

Like any evolutionary process, two key components shape these dynamics: the relevant **genotype–phenotype maps** (see Glossary) (which define the landscapes on which coevolution takes place) and the **population genetic environment** (the selection pressures, population sizes, mutation rates, and other factors that determine how evolution navigates the landscape) (Box 1). While both components are important and incompletely understood, here we focus on recent work exploiting technological advances to characterize the former: the genotype–phenotype maps of immune and viral proteins that define the coevolutionary landscape. Exploring these landscapes is a daunting prospect, because the size of the relevant sequence spaces is so massive that we cannot possibly explore these spaces comprehensively. However, by probing landscape structure in ways that are guided by evolution, we can hope to understand essential features that drive the coevolutionary process.

Inferences from observational data

Scientists have tracked pathogen sequence evolution since the advent of Sanger sequencing nearly 50 years ago, with a particular focus on viruses such as influenza. In the past two decades, rapid advances in sequencing technology have led to a dramatic expansion in the scale and

 https://doi.org/10.1016/j.it.2023.03.006

[1]Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, MA 02138, USA
[2]Department of Microbiology and Immunology, University of California at San Francisco, San Francisco, CA 94143, USA
[3]Department of Physics, Harvard University, Cambridge, MA 02138, USA
[4]NSF-Simons Center for Mathematical and Statistical Analysis of Biology, Harvard University, Cambridge, MA 02138, USA
[5]Quantitative Biology Initiative, Harvard University, Cambridge, MA 02138, USA
[6]These authors contributed equally to this work.

*Correspondence:
mdesai@oeb.harvard.edu (M.M. Desai).

Box 1. Fitness landscapes

We can think of the map between genotype and fitness as a '**fitness landscape**', which we often visualize as an actual landscape (complete with mountains and valleys), where the 'height' represents fitness and horizontal distances are proportional to the similarity between genotypes (see Figure 3 in main text) [124]. Populations can then be visualized as evolving across these landscapes by acquiring mutations, generally following an upward trajectory to higher fitness, with their exact dynamics depending on the population genetic environment (e.g., the selection pressures, population size, mutation rate, etc.). Hence, given some knowledge of these processes, fitness landscapes can be used to predict future evolution. A key question is the extent to which landscapes are 'smooth' (with steadily uphill paths towards higher fitness) versus 'rugged' (with local optima that can create traps and dead ends). Because ruggedness arises from non-additive (i.e., epistatic) interactions between mutations, it is particularly important to characterize these interactions.

While this low-dimensional intuition is appealing, it is also important to remember that genotype space is in fact vast and extremely high-dimensional. Even for a short peptide of ~20 amino acids, there are more than 10^{26} potential sequence variants, with a complex web of mutational relationships. The typical structure of such high-dimensional landscapes can run counter to our low-dimensional intuition (e.g., in considering the likelihood of local peaks and dead ends). In addition, the implicit assumptions that fitness landscapes are static breaks down when considering coevolving entities such as pathogens and immune receptors. Instead, these coevolutionary landscapes can act more as 'seascapes', which constantly shift in response to the opposing selection pressure [125]. For example, a virus may acquire antibody escape mutations, temporarily improving its fitness and allowing it to move upward in the landscape, but this region of the landscape will then shift downwards as antibodies mature to recognize the mutant virus [125].

The dynamic, high-dimensional nature of immune–pathogen coevolutionary landscapes makes the relationship between genotype and fitness impractical to characterize comprehensively using either experimental or computational methods. Instead, there have been significant advances in understanding the underlying structure of these landscapes by mapping the relationship between sequence and individual components of fitness (e.g., host receptor affinity, antibody escape) and the relative importance of these components in various selection environments (e.g., individuals with distinct immune responses). While seemingly more complicated, this type of decomposition can prove useful because these components are governed by biophysical and population genetic rules, mitigating the need to exhaustively chart sequence space [126].

scope of these surveillance studies and we now have access to detailed databases containing thousands to millions of sequences of viral pathogens, such as influenza, Zika, Ebola, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and many others [4,11–13]. Massive databases of bacterial pathogen sequences are also widely available [14,15]. These resources offer a unique window into pathogen evolution at the nucleotide level and often allow researchers to identify novel variants and track their dynamics through space and time [16,17].

Observational studies of the sequence diversity of immune receptors within an individual also date back a few decades and numerous studies have used these datasets to characterize the immune response [18–23]. As with the tracking of pathogen evolution, recent advances in sequencing methods have led to a proliferation of more comprehensive analyses of the B or T cell repertoires within individuals [24,25] and of how these repertoires change over time (e.g., in response to vaccination) [23,26,27]. These studies shed light into the evolution of our immune receptor repertoires, for example, by classifying B cell receptor (BCR) sequences into clonal lineages [28,29] and using within-lineage diversity to infer aspects of the **affinity maturation** process [30–32]. Aspects of the overall statistics of repertoire sequences (e.g., the frequency distribution of different variants) can also be used to infer parameters of the **V(D)J recombination** process that generates naive BCR sequences [33] and the influence of a history of pathogen exposure and/or vaccination on shaping repertoire statistics [30,34,35].

However, while advances in sequencing have dramatically improved our ability to observe sequence evolution in both pathogens and immune receptor repertoires, it remains more difficult to connect this sequence evolution with relevant phenotypes. That is, which of the mutations that we observe in influenza virus or SARS-CoV-2 evolution might lead to immune escape? Which of the BCR sequences binds a particular antigen and how has this changed across a clonal lineage

during affinity maturation? Addressing these questions is needed to understand the significance of observed pathogen and immune evolution and for any attempt to predict future coevolution.

To some extent, we can infer the phenotypic effects of specific mutations based on observational data (Figure 1). When multiple time points are available, the **relative fitness** of a specific pathogen strain can be directly estimated from its growth [36]. However, while this has been successfully applied to SARS-CoV-2 [37,38], there are potential caveats related to population structure and sampling biases, which can lead to misleading estimates of strain frequencies over time. In addition, these approaches are often not viable for less densely sequenced viruses. This type of analysis is also extremely difficult in the context of antibodies: as affinity maturation occurs entirely within lymph nodes, only the end result of this process is usually sequenced, so we lack any direct measurements of antibody frequency changes over time. Even experiments sampling directly from lymph nodes (in mice [39,40] or in humans [41,42]) result in the disruption of the germinal center, stopping the possibility of assessing an evolutionary process.

When time course data are not available, sequence variation at a snapshot in time can still provide some insight into selection pressures. For example, analyses based on the frequency of mutations or on the statistics of inferred phylogenetic relationships between sampled sequences have been used to analyze antigenic selection in influenza virus infections (and hence to predict future viral evolution) [43–45], as well as antibody responses to vaccination [42]. These approaches essentially allow us to infer past increases in frequency of specific pathogen strains or antibody variants (or groups of strains/variants). Some of this work also combines phylogenetic data with phenotypic information (e.g., **cross-neutralization** data for influenza [46–48]), which



Figure 1. Inferring fitness from observational data. (A) **Muller diagram** showing changes in frequency of lineages within a population over time. Each color refers to a specific genotype with a given fitness [corresponding to the phylogeny in (B); trajectories illustrate the changes in frequency of each lineage through time]. These frequency changes can be used to infer fitness of each genotype (though as noted in the text, this may be confounded by population structure, sampling biases, and other factors). (B) For illustration purposes, a hypothetical reconstructed phylogeny from a population sample collected at a single timepoint is shown. The structure of this phylogeny can be used to infer the fitness effect of each mutation.

Glossary

Affinity maturation: process by which antibodies increase their affinity against pathogens through rounds of somatic hypermutation and selection.
Antigenic drift: gradual accumulation of mutations in a pathogen, leading to changes in effectiveness of an immune response.
Biased mutation profile: set of probabilities of mutation types that are biased relative to other somatic mutations.
Cross-neutralization: the ability of antibodies to neutralize related pathogen strains.
Deep mutational scanning (DMS): method to analyze the effects of genetic variation by systematically introducing mutations into genes and measuring their effects on the corresponding phenotype.
Directed evolution: method of evolving biomolecules towards desired properties through experimentally imposed cycles of mutagenesis and selection.
Epistasis: non-additive interactions between mutations.
Extant sequences: sequences present in nature.
Fitness landscape: map between genotype (nucleotide sequence) and fitness (often represented by a proxy phenotype such as binding affinity, expression, antigenicity, etc.).
Focal sequence background: region of the protein sequence that is not mutated with respect to the starting (focal) sequence.
Fragment-antigen binding domain (Fab): part of an antibody that binds antigens. Constituted by two domains (constant and variable) for both the heavy and light chains. Used in antibody display.
Genotype–phenotype maps: map between genotype and a specific phenotype.
Historical contingency: influence of initial mutations on the evolutionary accessibility of future mutations.
Kinetic exclusion assays: measure the fraction of ligand bound to a receptor over a short period of time to quantify ligand–receptor interactions.
Low-dimensional antigenic space: hypothetical low-dimensional representation of all antigens that would retain accurate distances between immunological properties of each strain.

can improve the accuracy of inferred selection pressures but requires careful curation of the phenotypic data [43,47]. By contrast, other studies have focused entirely on phylogenetic information [49]. However, irrespective of these details, these types of analyses require relatively large datasets and make assumptions regarding evolutionary dynamics [50]. In addition, it is particularly challenging to apply these approaches to antibody sequence diversity, largely because of the properties of affinity maturation: namely, antibodies evolve in a handful of generations [39], under strong selection pressures [30], and with a **biased mutation profile** [51]. These complications violate assumptions of many population genetic models, making it difficult to apply standard methods.

Connecting genotype to phenotype

The limitations of these purely observational methods highlight the need for direct experimental measurements that connect genotypic diversity to the phenotypes that drive immune–pathogen coevolution. There are numerous phenotypes that influence the fitness of pathogens and antibodies and it is impossible to measure them all. However, several key phenotypes (e.g., protein stability, binding affinity to relevant target proteins, and neutralization of pathogenic strains by sera) are thought to be major drivers of immune–pathogen coevolution [52–56]. While these traits do not encompass all the selection pressures relevant for coevolution, they are useful proxies for important aspects of this process.

One approach to characterize these phenotypes involves direct analysis of protein structures, such as in early work using the structure of the influenza hemagglutinin (HA) protein to pinpoint sites of potential importance for immune evasion [57,58]. However, protein structure alone is usually insufficient to predict the effect of specific mutations. This motivates the use of methods that directly measure phenotypes, which often rely on traditional biochemical and immunological assays. Neutralization assays, for example, measure the ability of monoclonal antibodies (or of polyclonal sera) to inhibit viral infection of host cells [59]. This is relevant for analyzing population-level viral evolution [37,46], though it is less informative about intra-host immune evolution because it does not reveal the underlying antibody sequence changes. Other approaches tend to focus on more specific phenotypes, such as binding between surface proteins and antibodies. These measurements are typically made using purified proteins, using various techniques such as **surface plasmon resonance**, **kinetic exclusion assays**, titration-based methods, and ELISA [60–63]. While these measurements may not be as straightforward to interpret as neutralization data, they often provide a more direct insight into the mechanistic basis of antibody–pathogen interactions and hence can be more useful for making predictions.

Numerous studies have used these experimental measurements in combination with epidemiological models to infer and predict immune–pathogen coevolutionary dynamics. For example, serum reactivity studies can be used to define immune-similarity metrics between antigens, in the hope of defining a relatively **low-dimensional antigenic space** (see, e.g., [46,64,65]); one can then model **viral escape dynamics** through this space (see, e.g., [66]). Other studies make simplifying assumptions about the broader coevolutionary landscape (e.g., assuming that the effects of viral and antibody variants on binding affinities are additive to predict the dynamics of HIV-1 escape from monoclonal antibodies [67]).

A key limitation of these traditional phenotypic measurements is throughput: individual experiments can only test one pathogen strain or antibody at a time and are both time-consuming and expensive. As a result, studies have focused on relatively small sets of pathogen or antibody sequences. For example, one can isolate the relatively small fraction of B cells that bind a specific

Muller diagram: graphical representation showing the frequency of all sequence variants within a population over time.
Population genetic environment: factors that determine how a population generates variation and navigates the fitness landscape.
Relative fitness: measure of fitness compared with other variants in the population; this determines relative changes in frequency over time.
Reverse genetics: set of methods that infer the function of a gene by engineering specific mutations and observing their effects on phenotype.
Sequence logo plots: graphical representation of the effects of individual mutations on a given phenotype. Refers to additive effects in a specific focal background and does not include potential epistatic effects.
Single-chain variable fragment (scFv): fusion protein of antibody heavy and light variable regions. Used in antibody display.
Surface plasmon resonance: label-free method to measure the concentration of ligands bound to a surface coated with a receptor and, hence, quantify ligand–receptor interactions.
Tite-Seq: high-throughput approach to estimate the binding affinities of tens of thousands of protein variants to a given ligand.
Training neural networks: statistical approach for inferring parameters of a neural network based on a given data set.
V(D)J recombination: gene recombination process that generates naive antibody and T cell receptor diversity.
Viral escape dynamics: evolutionary changes in virus structure leading to immune escape.

antigen from blood samples and characterize the binding of these sequences to that antigen [68–71]. However, this still constrains the analysis to one small part of the landscape that was explored by affinity maturation in one particular individual. While one can alternatively create and analyze other types of sequence variants, basic constraints on throughput will still limit analysis to extremely small corners of the genotype space. This limitation can be circumvented by making simplifying assumptions (e.g., additivity of mutational effects) that allow us to infer the phenotypes of unobserved genotypes. However, these inferences are likely to fail because of widespread **epistasis** across the large diversity of viral strains and antibody sequences (Box 1). The key problem is that even small changes in viral or antibody proteins can have dramatic and context-dependent effects on their interactions [72].

Exploring large and high-dimensional landscapes

To more comprehensively analyze the large and high-dimensional genotype–phenotype maps that are relevant for immune–pathogen coevolution, extensive efforts have been devoted in recent years to developing methods to dramatically increase the throughput of the phenotypic measurements described earlier. These approaches typically use next-generation sequencing to measure relative enrichments of pathogen or immune receptor sequences across some experimentally imposed selection pressure, making it possible to conduct phenotypic measurements for large libraries of sequences in parallel (Figure 2). For example, numerous studies measure the effect of large libraries of sequence variants of influenza HA [73–76], SARS-CoV-2 spike protein [77,78], or HIV-1 envelope [79] on the ability of the corresponding viruses to infect target cells. Similar methods have been used to characterize the interactions between a library of antibody variants and their cognate antigen [80,81]. Other studies have developed '**Tite-Seq**' methods to make precise quantitative measurements of the binding dissociation constants of large libraries of antibody sequences to specific antigen proteins [54,82,83] (or conversely of large libraries of pathogen proteins to specific antibodies and target proteins [55,84–86]). These can be undertaken by displaying the library of interest on the surface of yeast, sorting the yeast cells into



Figure 2. High-throughput phenotypic measurements. (A) Large libraries of protein sequence variants can be assayed for various phenotypes of interest by conducting some assay, grouping variants based on the result of this assay [e.g., selecting using flow cytometry based on binding to a fluorescently labeled antibody as in (B), or based on some other experimental selection pressure as in (C)] and sequencing to determine the relative enrichment of each variant within each group. (B) A fluorescence-activated cell sorting (FACS)-based method to measure phenotypes such as binding or protein expression, in which the protein of interest is labeled with fluorescent tags for FACS-based cell sorting, is shown. (C) A direct passaging method, in which viral variants are incubated with target cells and allowed to replicate, is shown. After some time, successfully replicating (i.e., infectious) variants are isolated [95,136,137]. Abbreviation: NGS, next-generation sequencing.

bins based on binding of the surface-expressed protein to fluorescently labeled target, and sequencing these bins. In principle, similar types of approaches could conceivably be used to dramatically increase the throughput of other types of phenotypic testing; for example, this might be done by using methods analogous to Tite-Seq to measure the ability of large libraries of antibody variants to neutralize a specific viral strain, or the ability of a specific antibody sequence to neutralize a large library of viral variants.

High-throughput approaches often (though not always) rely on simplified or idealized systems, for example, viruses may be represented by a single protein that is recombinantly produced and antibodies may be truncated to enable expression on display systems [e.g., a **single-chain variable fragment (scFv)**, or **fragment-antigen binding domain (Fab)**] (Box 2); this can make it possible to explore phenotypes across a much larger portion of sequence space. However, despite these increases in throughput, the potential sequence space relevant for even a small viral protein (or a relatively short variable region in an antibody sequence) is so vast that we can still only hope to sample a tiny fraction of possible variants. Consequently, phenotypic measurements must be restricted to a well-chosen and relevant subset of genotypes. The choice of these subsets must be guided both by the specific research questions addressed (e.g., sampling variants in a way that is ideally related to the natural evolutionary process) and by technical constraints (particularly on the methods used to construct large variant libraries). Next, we describe three broad categories of approaches to the construction of these libraries used to explore distinct parts of antibody and pathogen sequence spaces (Figure 3, Key figure).

Local exploration

In the short term, evolution always acts locally, by sampling genotypes in the immediate mutational neighborhood of **extant sequences**. This has motivated extensive efforts to explore the local mutational landscape around antibody or pathogen sequences of particular interest (Figure 3A). For instance, numerous studies have used the **deep mutational scanning (DMS)** approach [87,88] to assess the phenotypic effect of various mutations on a specific **focal sequence background**. In these studies, libraries containing variants with one to a few amino acid substitutions from the focal sequence are generated and subjected to a selection pressure

Box 2. Relevant expression and display technologies

Numerous advances in protein expression technology over the past several decades have helped enable high-throughput measurements of various phenotypes. These technologies often rely on culturing phage or microbes, which produce recombinant protein either in solution or displayed on cell surfaces. Screening phenotypes of soluble proteins typically requires individual measurements for each variant because there is no way to link specific variants with their sequence in a bulk assay. While these soluble protein screens can often be conducted in 96- or 384-well plate format, the need for individual measurements still limits throughput significantly. For this reason, high-throughput phenotyping measurements are often carried out using either a protein display strategy (where the variant sequence is encoded on a plasmid or in the genome) or by linking a variant-specific tag to each protein molecule (e.g., using an mRNA or a ribosome display system [127]).

Protein display technologies have been established in phage, prokaryotic, and eukaryotic systems and have been used to measure various protein phenotypes, especially binding affinity [128–131]. For example, phage display was first introduced in 1985 [132] and has become a mainstay in novel therapeutic development, especially for antibody treatments. The relatively small size of bacteriophages makes it possible to analyze enormous libraries (up to tens of millions of variants) in a single measurement [132]. Although yeast-display libraries are substantially smaller than those in phage, they enable protein expression with eukaryotic post-translational modifications, which can crucially influence viral protein and antibody receptor function [131]. Still, most yeast-display systems are constrained to individual protein domains, limiting their utility for examining phenotypes involving multiple domains or oligomers. Recently, there have been several advances in human cell display technologies (e.g., engineered T cell receptor display), enabling display of full-length, natively processed viral proteins and immune receptors [78,133]. Separately, **reverse genetics** approaches enable construction of viral libraries [134,135], where viral protein variants are expressed in virions containing the corresponding genetic information and 'fitness' can be easily measured by viral replication.

Key figure

Strategies for exploring sequence space



Figure 3. We show an example of a short 15-residue peptide (with genotype space consisting of $15^{20} = 3 \times 10^{23}$ total possible sequence variants), which has evolved from a wild-type sequence to a mutant with five mutations at the sites indicated in blue. Shown are several types of variant libraries that explore different subsets of the sequence space (left) and lead to different observables (right). (A) Local exploration. These methods focus on the local mutational landscape around a specific focal genotype (here the wild-type or mutant sequences) using saturating mutagenesis (i.e., constructing all genotypes one mutation away from the focal genotype, 20*L total variants) or random mutagenesis. **Sequence logo plots** (right) are commonly used to summarize the impact (in the focal genotype) of all possible mutations at each site on the phenotype. This approach surveys both negative and positive mutational effects but does not provide information on epistasis. (B) Combinatorial exploration. Here the library contains all possible combinations of N mutations separating the mutant from the wild-type sequence (2^N total variants); both positive and negative mutational effects as well as epistatic interactions can be analyzed. All possible trajectories from wild-type to mutant sequences are shown on the right, with lines indicating the probability of each based on an evolutionary model given the measured phenotypes corresponding to each genotype (right). These probabilities can be used to define 'pathway accessibility', which refers to the likelihood of each possible pathway given a particular evolutionary model of natural selection and genetic drift. (C) Random exploration with selection. These libraries are generated with multiple rounds of random mutagenesis and selection; this approach is suited primarily to studying mutations with positive effects. The resulting population dynamics are shown on a Muller diagram, which shows the changes in frequency over time of each sequence variant (right).

such as binding affinity [89–94]. Following selection, relative enrichment of each variant is measured (more recent studies can also measure absolute binding affinities; see [55,85,86]).

DMS studies have identified mutations relevant to immune escape and pathogen function in many different viral systems involving influenza [73,75,95], hepatitis C [96], HIV-1 [79], and numerous SARS-CoV-2 variants [55,86], among others. This work has obvious direct implications for short-term evolutionary dynamics. For example, a number of studies on influenza virus show that the HA sequence is highly tolerant to mutations, enabling rapid **antigenic drift** [73,92,95,97]. Similar work on the SARS-CoV-2 spike protein has identified three receptor-binding domain (RBD) sites with mutations that increase binding affinity to the host cell receptor ACE2, while other RBD patches are constrained and therefore might be desirable targets for potential therapeutic antibodies [55,86]. Later DMS studies have identified other key spike protein sites in which mutations are likely to lead to immune escape variants [85,98]. Although these studies have largely been focused on viral proteins, the same strategies have been applied to investigate libraries of antibody variants, for example, by scanning complementarity-determining regions of relevant antibodies for mutations that enhance their binding to various antigens [81,82,99,100].

While this body of work has provided a wealth of insight into immune–pathogen coevolution, these approaches also have key limitations. The central constraint is that comprehensive DMS libraries are expensive (and/or laborious) to create, so while we can use this approach to comprehensively explore local sequence space, we can do so only around a small number of focal sequences of interest. Random mutagenesis can be used to create libraries more cheaply (at the cost of not being comprehensive), but the number of focal sequences we can explore remains relatively small. Thus, these approaches are generally limited to analyzing the landscapes that are relevant for very short-term coevolutionary dynamics around a handful of strains of interest. Some studies attempt to extrapolate to larger genetic distances. For example, this can be done by estimating the combined effects of multiple mutations based on their individual mutation effects in a DMS study [101], or by **training neural networks** (e.g., using SARS-CoV-2 receptor binding motif mutagenesis data [102]). However, widespread epistasis unavoidably means that the accuracy of any type of extrapolation of this kind will often fall off rapidly with mutational distance [103]. This places fundamental limits on the extent to which we can use these approaches to predict evolutionary dynamics.

Combinatorial exploration

Given the widespread importance of epistasis in immune–pathogen coevolution, a natural alternative approach is to construct combinatorial libraries of antibody or pathogen protein variants involving various combinations of mutations at some set of sites (Figure 3B). This allows us to characterize phenotypes that are relevant for potential longer-term evolutionary trajectories involving these sites (with the tradeoff that we are limited to just these sites and thus cannot explore potential trajectories involving other mutations elsewhere in the sequence). For example, recent work used this approach to show that epistasis between several SARS-CoV-2 Omicron BA.1 spike protein RBD mutations strongly interacted to modulate ACE2 binding affinity [78,104,105].

Many combinatorial studies attempt to construct all possible combinations of specific sets of mutations to provide a comprehensive characterization of the corresponding high-dimensional landscapes. This makes it possible to measure the phenotypes of all possible evolutionary intermediates between some ancestral sequence and its evolved descendant. These studies have been used to study protein evolution in a variety of contexts (e.g., to characterize constraints on the evolution of beta-lactamase [106–108] or to measure the importance of epistasis in a

fluorescent protein [109]). Recent work by us and others applied these methods to study immune–pathogen interactions, for example, by constructing all possible combinations of mutations leading from germline antibody sequences to several broadly neutralizing anti-influenza virus antibodies [54,83], or from the ancestral Wuhan Hu-1 strain of the SARS-CoV-2 spike protein RBD to the Omicron BA.1 variant [84,110]. We then measured the binding affinities of antibodies to relevant antigens, as well as the binding affinities of spike protein variants to human ACE2 and monoclonal antibodies. The structure of the resulting landscapes has provided some insight into how these antibody and viral strains evolved (e.g., that CR-9114, an extremely broadly neutralizing antibody, likely evolved in response to a specific sequential antigen exposure history).

These combinatorial studies allow us to comprehensively analyze the high-dimensional landscape defined by all possible evolutionary trajectories between the ancestral and evolved sequence (i.e., all possible orders in which this specific set of mutations could have occurred [107,111]). However, this is inherently retrospective and does not provide any insight into alternative potential evolutionary trajectories involving mutations at other sites. This is not a fundamental limitation of the approach: in principle, it is possible to construct combinatorial libraries involving any set of mutations of interest. For example, in future work it may be useful to analyze 'chimeric' libraries corresponding to variants across a broader phylogenetic tree; this could provide insight into how initial mutations constrain future evolution ('**historical contingency**') [103,112]. Other studies might focus on libraries of mutations that were identified based on structural analyses. Another promising avenue for future work is to integrate combinatorial approaches with data from DMS and mutagenesis studies. For example, one can identify a set of key mutations from DMS studies in a specific focal background and then explore the combinatorial landscape defined by these variants. Alternatively, one can conduct a combinatorial analysis, use it to identify key intermediate genotypes along likely evolutionary trajectories, and then conduct DMS or mutagenesis around these focal genotypes.

Regardless of how we select sets of mutations, a key constraint on combinatorial exploration of genotype–phenotype maps is the exponential explosion of the size of the library as the number of mutations involved increases. While it is generally relatively inexpensive to construct large libraries using combinatorial assembly methods, the scale at which we can measure corresponding phenotypes (even with high-throughput methods) becomes limiting. For example, Tite-Seq-based binding affinity assays are constrained by experimental limitations on flow cytometry throughput and sequencing costs; this renders the measurement of phenotypes of more than a few hundred thousand variants challenging [82]. Thus, if we wish to analyze combinatorially complete landscapes, we can consider at most, sets of 16–18 mutations. Alternatively, it is possible to consider combinatorial landscapes of larger sets of mutations in a less comprehensive way, for example, by grouping mutations into subsets and looking at all possible combinations of these subsets, or by making incomplete libraries consisting of a random sampling of possible mutation combinations [113]. This random sampling approach may be particularly promising, as it does broadly survey many potential epistatic interactions and hence may provide a better basis for extrapolating landscapes by inferring phenotypes of unobserved genotypes.

Random exploration guided by selection

A third approach to the characterization of high-dimensional genotype–phenotype maps is to attempt to directly recreate the process by which evolution samples these landscapes: mutational exploration combined with natural selection (Figure 3C). This essentially involves conducting **directed evolution**, in which one alternates rounds of mutagenesis with artificial selection for some phenotype of interest [114,115]. For example, a recent study conducted directed evolution of the SARS-CoV-2 spike protein RBD, finding that rounds of mutagenesis and selection for

expression and ACE2 binding led the original Wuhan Hu-1 strain to accumulate mutations that were common across the natural phylogeny [116].

Directed evolution studies are particularly widespread in the context of antibody affinity maturation, where numerous studies have evolved antibody sequences towards high affinity for a variety of specific antigens [117–122]. However, these studies have been primarily used for optimization, with the goal of rapidly producing antibodies with desired binding properties [115,123]. In principle, however, we could also use directed evolution in a more exploratory way, to artificially produce large numbers of replicate evolutionary trajectories through a high-dimensional landscape and measure relevant phenotypes of each intermediate. Similar approaches should also make it possible to emulate and analyze coevolutionary trajectories by simultaneously selecting antibodies to bind pathogen proteins and pathogen proteins to evade binding by corresponding antibodies. The variants identified in these directed evolution studies might then form the basis for subsequent combinatorial studies and the final evolved sequences (as well as key intermediates) might serve as focal genotypes for DMS analysis. These are exciting areas for future work, which offer the potential for entirely novel ways to explore high-dimensional coevolutionary landscapes.

Concluding remarks

As with any high-dimensional genotype–phenotype map, the central problem in empirically characterizing immune–pathogen coevolutionary landscapes is the massive scale of sequence space. Regardless of how rapidly we improve experimental methods and throughput, we will never be able to comprehensively survey even a small fraction of all possible genotypes. A key challenge is therefore to determine which combinations of the approaches described earlier, along with other strategies that we may not yet have conceived, can provide the most power for extrapolation (see Outstanding questions). That is, what types of measurements (and which computational approaches) will best allow us to accurately infer the larger-scale structure of the coevolutionary landscape from inevitably limited data? There is reason to be optimistic that this is possible: evolution itself cannot and does not comprehensively explore sequence space. Instead, it samples and selects trajectories based on relatively limited information. Thus, if we can collect a similar sort of information, it should be possible to make at least general statistical predictions about how evolution will act. This has the potential to improve our ability to understand, and eventually even predict, the effectiveness of antibody affinity maturation in response to vaccination or pathogen exposure and the corresponding evolution of pathogen immune escape.

We also note that throughout this review, we have focused on methods to empirically characterize genotype–phenotype maps. An equally important task is the development of theoretical and computational methods to predict how evolution navigates these complex high-dimensional landscapes. These methods can help us to understand what aspects of the landscapes are most crucial in shaping coevolutionary trajectories, which in turn can then shape future experimental directions.

Outstanding questions

What variant library structure provides the most power to infer the phenotypes of unobserved genotypes? How does the choice of model used for this inference affect the accuracy of this extrapolation and how does this accuracy change as a function of genetic distance?

What aspects of landscape structure are most crucial for determining coevolutionary dynamics and what types of empirical approaches can be used to most efficiently characterize these aspects?

What phenotypes or combinations of phenotypes are most relevant for determining selection pressures in nature? How can we improve the design and throughput of empirical methods to measure more complex phenotypes that may be better proxies for these pressures?

What general themes can emerge from the study of landscapes across many different pathogen and immune receptor proteins and phenotypes? Are there common patterns in the statistical structure of genotype–phenotype maps across many systems and, if so, what general implications does this have for immune–pathogen coevolution?

Acknowledgments

T.D. acknowledges support from the Human Frontier Science Program Postdoctoral Fellowship, A.M.P. acknowledges support from the Howard Hughes Medical Institute Hanna H. Gray Postdoctoral Fellowship, and M.M.D. acknowledges support from the NSF-Simons Center for Mathematical and Statistical Analysis of Biology at Harvard University, supported by NSF grant no. DMS-1764269, and the Harvard FAS Quantitative Biology Initiative, grant PHY-1914916 from the NSF and grant GM104239 from the NIH.

Declaration of interests

No interests are declared.

References

1. Tenthorey, J.L. *et al.* (2022) Evolutionary landscapes of host-virus arms races. *Annu. Rev. Immunol.* 40, 271–294
2. Brunham, R.C. *et al.* (1993) Bacterial antigenic variation, host immune response, and pathogen-host coevolution. *Infect. Immun.* 61, 2273–2276
3. Quadeer, A.A. *et al.* (2020) Deconvolving mutational patterns of poliovirus outbreaks reveals its intrinsic fitness landscape. *Nat. Commun.* 11, 377
4. Davis, B. *et al.* (2020) Viral and atypical respiratory co-infections in COVID-19: a systematic review and meta-analysis. *J. Am. Coll. Emerg. Physicians Open* 1, 533–548
5. Wheatley, A.K. *et al.* (2021) Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. *Nat. Commun.* 12, 1162
6. Xue, K.S. *et al.* (2017) Parallel evolution of influenza across multiple spatiotemporal scales. *eLife* 6, e26875
7. Jiang, N. *et al.* (2013) Lineage structure of the human antibody repertoire in response to influenza vaccination. *Sci. Transl. Med.* 5, 171ra19
8. Cobey, S. and Hensley, S.E. (2017) Immune history and influenza virus susceptibility. *Curr. Opin. Virol.* 22, 105–111
9. Tong, P. *et al.* (2021) Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. *Cell* 184, 4969–4980
10. Chen, Y. *et al.* (2022) Immune recall improves antibody durability and breadth to SARS-CoV-2 variants. *Sci. Immunol.* 7, eabp8328
11. Abdelrahman, Z. *et al.* (2020) Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza A respiratory viruses. *Front. Immunol.* 11, 552909
12. Bogner, P. *et al.* (2006) A global initiative on sharing avian flu data. *Nature* 442, 981
13. Shu, Y. and McCauley, J. (2017) GISAID: global initiative on sharing all influenza data - from vision to reality. *Euro Surveill.* 22, 30494
14. Zhang, T. *et al.* (2018) MPD: a pathogen genome and metagenome database. *Database (Oxford)* 2018, bay055
15. Shaw, L.P. *et al.* (2020) The phylogenetic range of bacterial and viral pathogens of vertebrates. *Mol. Ecol.* 29, 3361–3379
16. Hadfield, J. *et al.* (2018) Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics* 34, 4121–4123
17. Rambaut, A. *et al.* (2020) A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat. Microbiol.* 5, 1403–1407
18. Calis, J.J.A. and Rosenberg, B.R. (2014) Characterizing immune repertoires by high throughput sequencing: strategies and applications. *Trends Immunol.* 35, 581–590
19. Ravichandran, S. *et al.* (2021) Longitudinal antibody repertoire in "mild" versus "severe" COVID-19 patients reveals immune markers associated with disease severity and resolution. *Sci. Adv.* 7, eabf2467
20. Mitsunaga, E.M. and Snyder, M.P. (2020) Deep characterization of the human antibody response to natural infection using longitudinal immune repertoire sequencing. *Mol. Cell. Proteomics* 19, 278–293
21. Lee, J. *et al.* (2019) Persistent antibody clonotypes dominate the serum response to influenza over multiple years and repeated vaccinations. *Cell Host Microbe* 25, 367–376
22. Andrews, S.F. *et al.* (2019) Activation dynamics and immunoglobulin evolution of pre-existing and newly generated human memory B cell responses to influenza hemagglutinin. *Immunity* 51, 398–410
23. Horns, F. *et al.* (2020) Memory B cell activation, broad anti-influenza antibodies, and bystander activation revealed by single-cell transcriptomics. *Cell Rep.* 30, 905–913
24. Briney, B. *et al.* (2019) Commonality despite exceptional diversity in the baseline human antibody repertoire. *Nature* 566, 393–397
25. DeWitt 3rd, W.S. *et al.* (2018) Human T cell receptor occurrence patterns encode immune history, genetic background, and receptor specificity. *eLife* 7, e38358
26. Horns, F. *et al.* (2019) Signatures of selection in the human antibody repertoire: selective sweeps, competing subclones, and neutral drift. *Proc. Natl. Acad. Sci. U. S. A.* 116, 1261–1266
27. Hoehn, K.B. *et al.* (2019) Repertoire-wide phylogenetic models of B cell molecular evolution reveal evolutionary signatures of aging and vaccination. *Proc. Natl. Acad. Sci. U. S. A.* 116, 22664–22672
28. Gupta, N.T. *et al.* (2017) Hierarchical clustering can identify B cell clones with high confidence in Ig repertoire sequencing data. *J. Immunol.* 198, 2489–2499
29. Spisak, N. *et al.* (2022) Combining mutation and recombination statistics to infer clonal families in antibody repertoires. *bioRxiv* Published online December 22, 2022. https://doi.org/10.1101/2022.12.22.521661 Published online December 22, 2022
30. Nourmohammad, A. *et al.* (2019) Fierce selection and interference in B-cell repertoire response to chronic HIV-1. *Mol. Biol. Evol.* 36, 2184–2194
31. Hoehn, K.B. *et al.* (2022) Phylogenetic analysis of migration, differentiation, and class switching in B cells. *PLoS Comput. Biol.* 18, e1009885
32. Yermanos, A.D. *et al.* (2018) Tracing antibody repertoire evolution by systems phylogeny. *Front. Immunol.* 9, 2149
33. Marcou, Q. *et al.* (2018) High-throughput immune repertoire analysis with IGoR. *Nat. Commun.* 9, 561
34. Minervina, A.A. *et al.* (2021) Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection. *eLife* 10, e63502
35. Jackson, K.J.L. *et al.* (2014) Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements. *Cell Host Microbe* 16, 105–114
36. Marée, A.F. *et al.* (2000) Estimating relative fitness in viral competition experiments. *J. Virol.* 74, 11067–11072
37. Meijers, M. *et al.* (2022) Vaccination shapes evolutionary trajectories of SARS-CoV-2. *arXiv* Published online July 19, 2022. http://arxiv.org/abs/2207.09329 Published online July 19, 2022
38. Jankowiak, M. *et al.* (2022) Inferring selection effects in SARS-CoV-2 with Bayesian viral allele selection. *PLoS Genet.* 18, e1010540
39. Mesin, L. *et al.* (2016) Germinal center B cell dynamics. *Immunity* 45, 471–482
40. Mesin, L. *et al.* (2020) Restricted clonality and limited germinal center reentry characterize memory B cell reactivation by boosting. *Cell* 180, 92–106
41. Mudd, P.A. *et al.* (2022) SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. *Cell* 185, 603–613
42. Turner, J.S. *et al.* (2020) Human germinal centres engage memory and naive B cells after influenza vaccination. *Nature* 586, 127–132
43. Morris, D.H. *et al.* (2018) Predictive modeling of influenza shows the promise of applied evolutionary biology. *Trends Microbiol.* 26, 102–118
44. Neher, R.A. *et al.* (2016) Prediction, dynamics, and visualization of antigenic phenotypes of seasonal influenza viruses. *Proc. Natl. Acad. Sci. U. S. A.* 113, E1701–E1709
45. Kryazhimskiy, S. *et al.* (2011) Prevalence of epistasis in the evolution of influenza A surface proteins. *PLoS Genet.* 7, e1001301
46. Smith, D.J. *et al.* (2004) Mapping the antigenic and genetic evolution of influenza virus. *Science* 305, 371–376
47. Luksza, M. and Lässig, M. (2014) A predictive fitness model for influenza. *Nature* 507, 57–61
48. Strelkowa, N. and Lässig, M. (2012) Clonal interference in the evolution of influenza. *Genetics* 192, 671–682
49. Neher, R.A. *et al.* (2014) Predicting evolution from the shape of genealogical trees. *eLife* 3, e03568
50. Barrat-Charlaix, P. *et al.* (2021) Limited predictability of amino acid substitutions in seasonal influenza viruses. *Mol. Biol. Evol.* 38, 2767–2777
51. Spisak, N. *et al.* (2020) Learning the heterogeneous hypermutation landscape of immunoglobulins from high-throughput repertoire data. *Nucleic Acids Res.* 48, 10702–10712
52. Gong, L.I. *et al.* (2013) Stability-mediated epistasis constrains the evolution of an influenza protein. *eLife* 2, e00631
53. Rotem, A. *et al.* (2018) Evolution on the biophysical fitness landscape of an RNA virus. *Mol. Biol. Evol.* 35, 2390–2400

54. Phillips, A.M. *et al.* (2021) Binding affinity landscapes constrain the evolution of broadly neutralizing anti-influenza antibodies. *eLife* 10, e71393
55. Starr, T.N. *et al.* (2020) Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. *Cell* 182, 1295–1310
56. Tokuriki, N. and Tawfik, D.S. (2009) Stability effects of mutations and protein evolvability. *Curr. Opin. Struct. Biol.* 19, 596–604
57. Wilson, I.A. and Cox, N.J. (1990) Structural basis of immune recognition of influenza virus hemagglutinin. *Annu. Rev. Immunol.* 8, 737–771
58. Russell, R.J. *et al.* (2013) Influenza glycoproteins: hemagglutinin and neuraminidase. In *Textbook of Influenza*, pp. 67–100, John Wiley & Sons
59. Lu, Y. *et al.* (2021) Advances in neutralization assays for SARS-CoV-2. *Scand. J. Immunol.* 94, PMC8236914
60. van Regenmortel, M.H. and Azimzadeh, A. (2000) Determination of antibody affinity. *J. Immunoass.* 21, 211–234
61. Mattiasson, B. *et al.* (2010) Immunochemical binding assays for detection and quantification of trace impurities in biotechnological production. *Trends Biotechnol.* 28, 20–27
62. Blake 2nd, R.C. and Blake, D.A. (2004) Kinetic exclusion assays to study high-affinity binding interactions in homogeneous solutions. *Methods Mol. Biol.* 248, 417–430
63. Patching, S.G. (2014) Surface plasmon resonance spectroscopy for characterisation of membrane protein-ligand interactions and its potential for drug discovery. *Biochim. Biophys. Acta* 1838, 43–55
64. Einav, T. *et al.* (2022) Harnessing low dimensionality to visualize the antibody–virus landscape for influenza. *Nat. Comput. Sci.* 3, 164–173
65. Smith, D.J. *et al.* (1997) Deriving shape space parameters from immunological data. *J. Theor. Biol.* 189, 141–150
66. Marchi, J. *et al.* (2021) Antigenic waves of virus-immune coevolution. *Proc. Natl. Acad. Sci. U. S. A.* 118, e2103398118
67. LaMont, C. *et al.* (2022) Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1. *eLife* 11, e76004
68. Franz, B. *et al.* (2011) Ex vivo characterization and isolation of rare memory B cells with antigen tetramers. *Blood* 118, 348–357
69. Hayakawa, K. *et al.* (1987) Isolation of high-affinity memory B cells: phycoerythrin as a probe for antigen-binding cells. *Proc. Natl. Acad. Sci. U. S. A.* 84, 1379–1383
70. Ouisse, L.-H. *et al.* (2017) Antigen-specific single B cell sorting and expression-cloning from immunoglobulin humanized rats: a rapid and versatile method for the generation of high affinity and discriminative human monoclonal antibodies. *BMC Biotechnol.* 17, 3
71. Mahendra, A. *et al.* (2022) Honing-in antigen-specific cells during antibody discovery: a user-friendly process to mine a deeper repertoire. *Commun. Biol.* 5, 1157
72. Koel, B.F. *et al.* (2013) Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. *Science* 342, 976–979
73. Thyagarajan, B. and Bloom, J.D. (2014) The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin. *eLife* 3, e03300
74. Doud, M.B. *et al.* (2017) Complete mapping of viral escape from neutralizing antibodies. *PLoS Pathog.* 13, e1006271
75. Wu, N.C. *et al.* (2020) Different genetic barriers for resistance to HA stem antibodies in influenza H3 and H1 viruses. *Science* 368, 1335–1340
76. Phillips, A.M. *et al.* (2018) Enhanced ER proteostasis and temperature differentially impact the mutational tolerance of influenza hemagglutinin. *eLife* 7, e38795
77. Crawford, K.H.D. *et al.* (2020) Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. *Viruses* 12, 513
78. Javanmardi, K. *et al.* (2022) Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein. *Cell Host Microbe* 30, 1242–1254
79. Haddox, H.K. *et al.* (2018) Mapping mutational effects along the evolutionary landscape of HIV envelope. *eLife* 7, e34420
80. Koenig, P. *et al.* (2017) Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding. *Proc. Natl. Acad. Sci. U. S. A.* 114, E486–E495
81. Forsyth, C.M. *et al.* (2013) Deep mutational scanning of an antibody against epidermal growth factor receptor using mammalian cell display and massively parallel pyrosequencing. *mAbs* 5, 523–532
82. Adams, R.M. *et al.* (2016) Measuring the sequence-affinity landscape of antibodies with massively parallel titration curves. *eLife* 5, e23156
83. Phillips, A.M. *et al.* (2023) Hierarchical sequence-affinity landscapes shape the evolution of breadth in an anti-influenza receptor binding site antibody. *eLife* 12, e83628
84. Moulana, A. *et al.* (2022) Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1. *Nat. Commun.* 13, 7011
85. Greaney, A.J. *et al.* (2021) Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. *Cell Host Microbe* 29, 463–476
86. Starr, T.N. *et al.* (2022) Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution. *Science* 377, 420–424
87. Fowler, D.M. *et al.* (2014) Measuring the activity of protein variants on a large scale using deep mutational scanning. *Nat. Protoc.* 9, 2267–2284
88. Araya, C.L. and Fowler, D.M. (2011) Deep mutational scanning: assessing protein function on a massive scale. *Trends Biotechnol.* 29, 435–442
89. Sourisseau, M. *et al.* (2019) Deep mutational scanning comprehensively maps how Zika envelope protein mutations affect viral growth and antibody escape. *J. Virol.* 93, e01291-19
90. Russell, C.J. *et al.* (2018) Influenza hemagglutinin protein stability, activation, and pandemic risk. *Trends Microbiol.* 26, 841–853
91. Wu, N.C. *et al.* (2017) In vitro evolution of an influenza broadly neutralizing antibody is modulated by hemagglutinin receptor specificity. *Nat. Commun.* 8, 15371
92. Wu, N.C. *et al.* (2014) High-throughput profiling of influenza A virus hemagglutinin gene at single-nucleotide resolution. *Sci. Rep.* 4, 4942
93. Duenas-Decamp, M. *et al.* (2016) Saturation mutagenesis of the HIV-1 envelope CD4 binding loop reveals residues controlling distinct trimer conformations. *PLoS Pathog.* 12, e1005988
94. Wang, B. *et al.* (2022) ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants. *Emerg Microbes Infect.* 11, 1488–1499
95. Lee, J.M. *et al.* (2018) Deep mutational scanning of hemagglutinin helps predict evolutionary fates of human H3N2 influenza variants. *Proc. Natl. Acad. Sci. U. S. A.* 115, E8276–E8285
96. Qi, H. *et al.* (2014) A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity. *PLoS Pathog.* 10, e1004064
97. Doud, M. and Bloom, J. (2016) Accurate measurement of the effects of all amino-acid mutations on influenza hemagglutinin. *Viruses* 8, 155
98. Starr, T.N. *et al.* (2021) Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. *Science* 371, 850–854
99. Fujino, Y. *et al.* (2012) Robust in vitro affinity maturation strategy based on interface-focused high-throughput mutational scanning. *Biochem. Biophys. Res. Commun.* 428, 395–400
100. Hanning, K.R. *et al.* (2022) Deep mutational scanning for therapeutic antibody engineering. *Trends Pharmacol. Sci.* 43, 123–135
101. Greaney, A.J. *et al.* (2022) An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain. *Virus Evol.* 8, veac021
102. Taft, J.M. *et al.* (2022) Deep mutational learning predicts ACE2 binding and antibody escape to combinatorial mutations in the SARS-CoV-2 receptor-binding domain. *Cell* 185, 4008–4022
103. Park, Y. *et al.* (2022) Epistatic drift causes gradual decay of predictability in protein evolution. *Science* 376, 823–830

104. Dejnirattisai, W. *et al.* (2022) SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. *Cell* 185, 467–484
105. Zhou, D. *et al.* (2021) Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. *Cell* 184, 2348–2361
106. Meini, M.-R. *et al.* (2015) Quantitative description of a protein fitness landscape based on molecular features. *Mol. Biol. Evol.* 32, 1774–1787
107. Weinreich, D.M. *et al.* (2006) Darwinian evolution can follow only very few mutational paths to fitter proteins. *Science* 312, 111–114
108. Schenk, M.F. *et al.* (2013) Patterns of epistasis between beneficial mutations in an antibiotic resistance gene. *Mol. Biol. Evol.* 30, 1779–1787
109. Poelwijk, F.J. *et al.* (2019) Learning the pattern of epistasis linking genotype and phenotype in a protein. *Nat. Commun.* 10, 4213
110. Moulana, A. *et al.* (2023) The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution. *eLife* 12, e83442
111. McCandlish, D.M. (2011) Visualizing fitness landscapes. *Evolution* 65, 1544–1558
112. Starr, T.N. *et al.* (2017) Alternative evolutionary histories in the sequence space of an ancient protein. *Nature* 549, 409–413
113. Olson, C.A. *et al.* (2014) A comprehensive biophysical description of pairwise epistasis throughout an entire protein domain. *Curr. Biol.* 24, 2643–2651
114. Bowers, P.M. *et al.* (2018) The use of somatic hypermutation for the affinity maturation of therapeutic antibodies. *Methods Mol. Biol.* 1827, 479–489
115. Romero, P.A. and Arnold, F.H. (2009) Exploring protein fitness landscapes by directed evolution. *Nat. Rev. Mol. Cell Biol.* 10, 866–876
116. Zahradník, J. *et al.* (2021) SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. *Nat. Microbiol.* 6, 1188–1198
117. Persson, H. *et al.* (2018) In vitro evolution of antibodies inspired by in vivo evolution. *Front. Immunol.* 9, 1391
118. Chan, D.T.Y. *et al.* (2020) Extensive sequence and structural evolution of arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturation. *Proc. Natl. Acad. Sci. U. S. A.* 117, 16949–16960
119. Rajpal, A. *et al.* (2005) A general method for greatly improving the affinity of antibodies by using combinatorial libraries. *Proc. Natl. Acad. Sci. U. S. A.* 102, 8466–8471
120. Jespers, L.S. *et al.* (1994) Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. *Biotechnology (N Y)* 12, 899–903
121. Boder, E.T. *et al.* (2000) Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. *Proc. Natl. Acad. Sci. U. S. A.* 97, 10701–10705
122. Rappazzo, C.G. *et al.* (2021) Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. *Science* 371, 823–829
123. Daugherty, P.S. *et al.* (2000) Quantitative analysis of the effect of the mutation frequency on the affinity maturation of single chain Fv antibodies. *Proc. Natl. Acad. Sci. U. S. A.* 97, 2029–2034
124. de Visser, J.A.G.M. and Krug, J. (2014) Empirical fitness landscapes and the predictability of evolution. *Nat. Rev. Genet.* 15, 480–490
125. Mustonen, V. and Lässig, M. (2009) From fitness landscapes to seascapes: non-equilibrium dynamics of selection and adaptation. *Trends Genet.* 25, 111–119
126. Bloom, J.D. and Arnold, F.H. (2009) In the light of directed evolution: pathways of adaptive protein evolution. *Proc. Natl. Acad. Sci. U. S. A.* 106, 9995–10000
127. Chan, D.T.Y. and Groves, M.A.T. (2021) Affinity maturation: highlights in the application of in vitro strategies for the directed evolution of antibodies. *Emerg. Top. Life Sci.* 5, 601–608
128. Moore, S.J. and Cochran, J.R. (2012) Engineering knottins as novel binding agents. *Methods Enzymol.* 503, 223–251
129. Gai, S.A. and Wittrup, K.D. (2007) Yeast surface display for protein engineering and characterization. *Curr. Opin. Struct. Biol.* 17, 467–473
130. Hunter, S.A. and Cochran, J.R. (2016) Cell-binding assays for determining the affinity of protein-protein interactions: technologies and considerations. *Methods Enzymol.* 580, 21–44
131. Boder, E.T. and Wittrup, K.D. (1997) Yeast surface display for screening combinatorial polypeptide libraries. *Nat. Biotechnol.* 15, 553–557
132. Smith, G.P. (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. *Science* 228, 1315–1317
133. Vazquez-Lombardi, R. *et al.* (2022) High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity. *Immunity* 55, 1953–1966
134. Hoffmann, E. *et al.* (2000) A DNA transfection system for generation of influenza A virus from eight plasmids. *Proc. Natl. Acad. Sci. U. S. A.* 97, 6108–6113
135. Bloom, J.D. (2014) An experimentally determined evolutionary model dramatically improves phylogenetic fit. *Mol. Biol. Evol.* 31, 1956–1978
136. Phillips, A.M. *et al.* (2017) Host proteostasis modulates influenza evolution. *eLife* 6, e28652
137. Acevedo, A. *et al.* (2014) Mutational and fitness landscapes of an RNA virus revealed through population sequencing. *Nature* 505, 686–690